Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12

Journal of Immunology

Volumn 164, Issue 11, 2000, Pages 6041-6045

  Heidecker, Leonora ^a   Brasseur, Francis ^a   Probst Kepper, Michael ^a,b   Guéguen, Maryse ^a,c   Boon, Thierry ^a   Van Den Eynde, Benoît J ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN MAGE A12; UNCLASSIFIED DRUG;

AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; ESOPHAGUS CARCINOMA; GENE EXPRESSION REGULATION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MALE; MELANOMA; PRIORITY JOURNAL;

EID: 0034120928     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.11.6041     Document Type: Article

References (40)

1. Van den Eynde, B., and P. van der Bruggen. 1997. T cell-defined tumor antigens. Curr. Opin. Immunol. 9:684.
2. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
3. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
4. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
5. Boël, P., C. Wildmann, M.-L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
6. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
7. van der Bruggen, P., J.-P. Szikora, P. Boël, C. Wildmann, M. Somville, M. Sensi, and T. Boon. 1994. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur. J. Immunol. 24: 2134.
8. Huang, L.-Q., F. Brasseur, A. Serrano, E. De Plaen, P. van der Bruggen, T. Boon, and A. Van Pel. 1999. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J. Immunol. 162:6849.
9. Zom, E., and T. Hercend. 1999. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur. J. Immunol. 29:602.
10. van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boël, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MACE-3. Eur. J. Immunol. 24:3038.
11. Chaux, P., R. Luiten, N. Demotte, V. Vantomme, V. Stroobant, C. Traversari, V. Russo, E. Schultz, G. R. Cornelis, T. Boon, et al. 1999. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163: 2928.
12. Duffour, M.-T., P. Chaux, C. Lurquin, G. Cornelis, T. Boon, and P. van der Bruggen. 1999. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur. J. Immunol. 29:3329.
13. Guéguen, M., J.-J. Patard, B. Gaugler, F. Brasseur, J.-C. Renauld, P. J. Van Cangh, T. Boon, and B. Van den Eynde. 1998. An antigen recognized by autologous CTL on a human bladder carcinoma. J. Immunol. 160:6188.
14. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99.
15. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203.
16. Atherton, E., C. J. Logan, and R. C. Sheppard. 1981. Peptide synthesis. Part 2. Procedures for solid phase synthesis using Nα-fluorenylmethysoxycarbamylamino-acid on polymide supports: synthesis of substance P and of acyl carrier protein 65-74 decapeptide. J. Chem. Soc. Lond. Perkin Trans. 1:538.
17. Boon, T., J. Van Snick, A. Van Pel, C. Uyttenhove, and M. Marchand. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J. Exp. Med. 152:1184.
18. De Plaen, E., K. Arden, C. Traversari, J. J. Gaforio, J.-P. Szikora, C. De Smet, F. Brasseur, P. van der Bruggen, B. Lethé, C. Lurquin, et al. 1994. Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40:360.
19. Weynants, P., B. Lethé, F. Brasseur, M. Marchand, and T. Boon. 1994. Expression of MAGE genes by non-small-cell lung carcinomas. Int. J. Cancer 56:826.
20. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
21. van der Vlies, S. A., C. E. M. Voorter, and E. M. van den Berg-Loonen. 1998. A reliable and efficient high resolution typing method for HLA-C using sequence-based typing. Tissue Antigens 52:558.
22. Haas, G. G., Jr., O. J. D'Cruz, and L. E. De Bault. 1988. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am. J. Reprod. Immunol. Microbiol. 18:47.
23. Takahashi, K., S. Shichijo, M. Noguchi, M. Hirohata, and K. Itoh. 1995. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 55:3478.
24. Herman, J., P. van der Bruggen, I. Luescher, S. Mandruzzato, P. Romero, J. Thonnard, K. Fleischhauer, T. Boon, and P. G. Coulie. 1996. A peptide encoded by the human gene MACE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenetics 43:377.
25. Lurquin, C., C. De Smet, F. Brasseur, F. Muscatelli, V. Martelange, E. De Plaen, R. Brasseur, A. P. Monaco, and T. Boon. 1997. Two members of the human MAGEB gene family located in Xp.21.3 are expressed in tumors of various histological origins. Genomics 46:397.
26. Lucas, S., C. De Smet, K. C. Arden, C. S. Viars, B. Lethé, C. Lurquin, and T. Boon. 1998. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 58:743.
27. Lucas, S., F. Brasseur, and T. Boon. 1999. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 59:4100.
28. Pold, M., J. Zhou, G. L. Chen, J. M. Hall, R. A. Vescio, and J. R. Berenson. 1999. Identification of a new, unorthodox member of the MAGE gene family. Genomics 59:161.
29. Morales, A. 1992. From the 19th to the 21st centuries: BCG in the treatment of superficial bladder cancer. Eur. Urol. 21:2.
30. Herr, H. W., D. M. Schwalb, and F. Zhang. 1995. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer. J. Clin. Oncol. 13:1404.
31. Hudson, M. A., and H. W. Herr. 1995. Carcinoma in situ of the bladder. J. Urol. 153:564.
32. Patard, J.-J., F. Brasseur, S. Gil-Diez, F. Radvanyi, M. Marchand, P. François, A. Abi Aad, P. Van Cangh, C. C. Abbou, D. Chopin, et al. 1995. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer 64:60.
33. Marchand, M., C. Chatzopoulous, F. Brasseur, M. Guéguen, J.-J. Patard, P. François, P. J. Van Cangh, and B. J. Van den Eynde. 1996. Tumour antigens recognized by cytolytic T lymphocytes: perspectives for specific immunotherapy of bladder cancer and other genitourinary tumours. Eur. Urol. Update Ser. 5:118.
34. Boon, T., and B. Van den Eynde. 1999. Shared tumor-specific antigens. In Principles and Practice of the Biologic Therapy of Cancer. S. A. Rosenberg, ed. In press.
35. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dréno, M.-H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.
36. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
37. + T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens. J. Immunol. Methods 203:141.
38. Pass, H. A., S. L. Schwarz, J. R. Wunderlich, and S. A. Rosenberg. 1998. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4:316.
39. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
40. Romero, P., J.-C. Cerottini, and G. A. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol. Med. Today 4:305.